Research effects
As a growth hormone-releasing hormone (GHRH) analogue, CJC-1295 NO DAC (the version without the drug affinity complex, also known as Mod GRF 1-29) demonstrates significant potential in stimulating endogenous growth hormone secretion.
Efficacy
Users commonly report increased muscle strength, reduced body fat, and improvements in sleep quality and skin elasticity. Compared to the DAC-containing version, the NO DAC version has a shorter half-life, allowing it to better mimic the natural pulsatile rhythm of growth hormone secretion, which is considered more physiological and may help avoid risks associated with persistently elevated growth hormone levels. In clinical applications, this class of peptides has been studied for improving age-related decline in growth hormone levels, helping to maintain muscle mass, bone density, and overall vitality.
Research mechanism
CJC-1295 NO DAC acts by binding to and activating the growth hormone-releasing hormone receptor (GHRH-R) on the anterior pituitary gland. The peptide contains a modified amino acid sequence that confers resistance to protease degradation, significantly extending its in vivo activity duration. Upon receptor binding, it activates the downstream cAMP/PKA signaling pathway, stimulating growth hormone synthesis and release. Notably, the short-acting nature of the NO DAC version prevents sustained, plateau-like elevation of growth hormone levels, instead maintaining a pulsatile release pattern that more closely aligns with the body's circadian rhythm. This pulsatile secretion is essential for maintaining normal physiological feedback regulation, effectively avoiding excessive elevation of insulin-like growth factor-1 (IGF-1) that can result from continuously high growth hormone levels, thereby better maintaining glucose metabolic balance while enhancing anabolic signaling.